What a zoo on Twitter. This was the one... "please

New Post Public Reply Private Reply Replies (2) Message Board
redspeed
310
What a zoo on Twitter.

This was the one...

"please tell us why your product is any different? Is it because you’ve exposed your product to a “plant virus” to make it stronger as claimed a couple months ago? Please tell us what plant virus you used ? Genuinely curious"

Must be the brain fog.

What time does the Penelope pity party start?

"I’m glad you’ve had good experiences with the company. The CEO was hostile to me right out of the gate . I’m aware of at least two other women in the LC community who’ve had the same experience. The opportunity 4 him to do positive outreach and effective communication was not taken."

baby-eating.gif

Don't let facts get in the way of a colorful story. Mind was made up from the get go which is the problem with some people that can't have an open mind.
·
Apr 28
Think of all the people who could be helped if the active ingredient in the product, gromwell root, was clinically studied for efficacy. It’s TCM, and very inexpensive. I’m going to try it in the 20 dollar tincture form, because there’s no freaking way it’s worth 300 bucks.

Apr 28
I don’t need to talk to the CEO of the company to know that they are trying to rip off desperate people. You don’t try to get a patent on your mysterious “extraction method” of a cheap plant out of the kindness of your heart.

Exactly who was hostile? You didn't even want to talk to the company as you were to busy 'ranting'. Of course the stock trolls didn't help either.

https://twitter.com/G_Commish/status/1519651606651973633

OK, I'm done. Back to focusing on the company

Todos Med Ltd. (TOMDF) Stock Research Links

TOMDF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 19

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 24

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 30

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 18

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 23

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 25

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading

Top 5 Most Recently Viewed Articles

Alterity Therapeutics Showcases Innovation at Healthcare Event

Updated Category News Views 142

Alterity Therapeutics to Present at a Virtual Healthcare Conference Alterity Therapeutics, a biotechnology firm dedicated to developing treatments for neurodegenerative diseases, has recently announced its participation in an upcoming healthcare virtual conference. The event will shine a spotlight on influential healthcare companies and their innovative approaches to...

Continue Reading
Important Update for Toronto-Dominion Bank Investors on Lawsuit

Updated Category News Views 58

Update for Investors in Toronto-Dominion Bank Kahn Swick & Foti, LLC, led by the experienced former Louisiana Attorney General Charles C. Foti, Jr., is reminding investors that significant changes are arriving for shareholders of Toronto-Dominion Bank (NYSE: TD). As the legal landscape evolves, those who experienced losses may want to take immediate action regarding their...

Continue Reading
GCC's Quarterly Performance Analysis: Key Insights Revealed

Updated Category News Views 221

GCC Reports Significant First Quarter Financials GCC, S.A.B. de C.V. (BMV: GCC*), recognized as a premier supplier and producer of cement, concrete, and aggregates, has shared its financial results for the first quarter. Despite facing various challenges, GCC's performance metrics reveal a resilience that is noteworthy. Q1 2025 Highlights In the first quarter of 2025, GCC...

Continue Reading
Indonesia's IDX Composite Index Declines Amid Market Pressures

Updated Category News Views 116

Overview of Recent Market Movements in Indonesia Indonesia's stock market experienced a downturn at the close of trading, influenced by various sectors showing significant losses. The IDX Composite Index reflected a decrease of 0.98%, marking a notable dip to a one-month low. This downturn is primarily attributed to declines in several key sectors, including...

Continue Reading
Blink Charging Achieves Advanced Certification for EV Chargers

Updated Category News Views 130

Blink Charging Receives Prestigious OCPP 2.0.1 Certification Blink stands out as one of just five EV charging companies in the U.S. to earn this coveted certification. Bowie, Md. – Blink Charging Co. (NASDAQ: BLNK), a prominent name in electric vehicle (EV) charging equipment and services, has proudly announced that its Series 7, 8, and 9 charger models have...

Continue Reading